This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n11http://localhost/temp/predkladatel/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n14http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
skoshttp://www.w3.org/2004/02/skos/core#
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11150%2F05%3A00004778%21RIV08-MSM-11150___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n16http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11150%2F05%3A00004778%21RIV08-MSM-11150___
rdf:type
skos:Concept n14:Vysledek
dcterms:description
The aim of the European First Episode Schizophrenia Trial (EUFEST) is to compare treatment with amisulpride, quetiapine, olanzapine and ziprasidone to a low dose of haloperidol in an unselected sample of first episode schizophrenia patients with minimal prior exposure to antipsychotics. At present, more than 400 patients have been recruited and randomized in the following countries: Austria, Belgium, Bulgaria, Czech Republic, Germany, France, Israel, Italy, the Netherlands, Poland, Rumania, Spain, Sweden and Switzerland: The study should be finished by the end of 2006 and it is expected that results will yield relevant clinical information with regard to the effectiveness of the second generation antipsychotics. This effort represents the first independently designed trans-European schizophrenia treatment trial. Cíle: cílem the European first episode schizopherenia trial (EUFEST) je porovnání léčby amisulpridem, quetiapinem, olanzapinem a ziprasidonem s nízkými dávkami haloperidolu na vzorku pacientů po prvním ataku schizofrenie, kteří mají minimální předchozí zkušenosti s antipsychotiky. Do dnešní doby do studie vstoupilo více než 400 pacientů ze těchto zemí: Rakousko, Belgie, Bulharsko, Česká republika, Německo, Francie, Izrael, Itálie, Holandsko, Polsko, Rumunsko, atd. Studie by měla skončit na konci roku 2006. The aim of the European First Episode Schizophrenia Trial (EUFEST) is to compare treatment with amisulpride, quetiapine, olanzapine and ziprasidone to a low dose of haloperidol in an unselected sample of first episode schizophrenia patients with minimal prior exposure to antipsychotics. At present, more than 400 patients have been recruited and randomized in the following countries: Austria, Belgium, Bulgaria, Czech Republic, Germany, France, Israel, Italy, the Netherlands, Poland, Rumania, Spain, Sweden and Switzerland: The study should be finished by the end of 2006 and it is expected that results will yield relevant clinical information with regard to the effectiveness of the second generation antipsychotics. This effort represents the first independently designed trans-European schizophrenia treatment trial.
dcterms:title
The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial Evropská studie u prvních epizod schizofrenie (EUFEST): zdůvodnění a záměr studie The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial
skos:prefLabel
The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial The European First Episode Schizophrenia Trial (EUFEST): Rationale and design of the trial Evropská studie u prvních epizod schizofrenie (EUFEST): zdůvodnění a záměr studie
skos:notation
RIV/00216208:11150/05:00004778!RIV08-MSM-11150___
n4:strany
147;156
n4:aktivita
n17:S
n4:aktivity
S
n4:cisloPeriodika
2-3
n4:dodaniDat
n16:2008
n4:domaciTvurceVysledku
n6:2617536
n4:druhVysledku
n15:J
n4:duvernostUdaju
n7:S
n4:entitaPredkladatele
n13:predkladatel
n4:idSjednocenehoVysledku
520661
n4:idVysledku
RIV/00216208:11150/05:00004778
n4:jazykVysledku
n12:eng
n4:klicovaSlova
European; First; Episode; Schizophrenia; Trial; EUFEST; Rationale; design; trial
n4:klicoveSlovo
n9:trial n9:design n9:EUFEST n9:First n9:Rationale n9:European n9:Trial n9:Episode n9:Schizophrenia
n4:kodStatuVydavatele
NL - Nizozemsko
n4:kontrolniKodProRIV
[32A540FE400C]
n4:nazevZdroje
Schizophrenia Research
n4:obor
n10:FL
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
20
n4:rokUplatneniVysledku
n16:2005
n4:svazekPeriodika
78
n4:tvurceVysledku
Libiger, Jan
s:issn
0920-9964
s:numberOfPages
10
n11:organizacniJednotka
11150